A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.

被引：1
|
作者：
Kristeleit, Rebecca Sophie
Brown, Nicholas F.
Hess, Dagmar
Joerger, Markus
Von Moos, Roger
Rodon, Jordi
Hierro, Cinta
Childs, Alexa
Stathis, Anastasios
Dimitrijevic, Sasa
Stumm, Michael
Herrmann, Richard
Sessa, Cristiana
Bize, Vincent
Hess, Viviane
Wicki, Andreas
机构：
[1] UCL, Inst Canc, London, England
[2] UCL, London, England
[3] Kantonsspital St Gallen, Eggersriet, Switzerland
[4] Cantonal Hosp, St Gallen, Switzerland
[5] VHIO, Barcelona, Spain
[6] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[7] PIQUR Therapeut AG, Basel, Switzerland
[8] Piqur Pharma, Basel, Switzerland
[9] Univ Hosp, Riehen, Switzerland
[10] IOSI, Bellinzona, Switzerland
[11] SAKK Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
[12] Univ Spital Basel, Basel, Switzerland
[13] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2592
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.
    Amin, Hesham M.
    Falchook, Gerald Steven
    Fu, Siqing
    Hong, David S.
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Janku, Filip
    Klevesath, Manfred B.
    Jego, Virginie
    Johne, Andreas
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Jonasch, Eric
    Zojwalla, Naseem J.
    Wang, Keshi
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Rodon, Jordi
    Perez-Fidalgo, Alejandro
    Krop, Ian E.
    Burris, Howard
    Guerrero-Zotano, Angel
    Britten, Carolyn D.
    Becerra, Carlos
    Schellens, Jan
    Richards, Donald A.
    Schuler, Martin
    Abu-Khalaf, Maysa
    Johnson, Faye M.
    Ranson, Malcolm
    Edenfield, Jeff
    Silva, Antonio P.
    Hackl, Wolfgang
    Quadt, Cornelia
    Demanse, David
    Duval, Vincent
    Baselga, Jose
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 285 - 298
  • [44] Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
    Shapiro, G.
    Kwak, E.
    Baselga, J.
    Rodon, J.
    Scheffold, C.
    Laird, A. D.
    Bedell, C.
    Edelman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Jordi Rodon
    Alejandro Pérez-Fidalgo
    Ian E. Krop
    Howard Burris
    Angel Guerrero-Zotano
    Carolyn D. Britten
    Carlos Becerra
    Jan Schellens
    Donald A. Richards
    Martin Schuler
    Maysa Abu-Khalaf
    Faye M. Johnson
    Malcolm Ranson
    Jeff Edenfield
    Antonio P. Silva
    Wolfgang Hackl
    Cornelia Quadt
    David Demanse
    Vincent Duval
    Jose Baselga
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 285 - 298
  • [46] First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors
    Papadopoulos, Kyriakos P.
    Borazanci, Erkut
    Von Hoff, Daniel
    Gandhi, Leena
    Patnaik, Amita
    Tachibana, Masaya
    Zahir, Hamim
    Gajee, Roohi
    Goldberg, Tern
    Senaldi, Giorgio
    Ou, Sai-Hong
    CANCER RESEARCH, 2016, 76
  • [47] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Tibes, Raoul
    Fine, Gil
    Choy, Gavin
    Redkar, Sanjeev
    Taverna, Pietro
    Oganesian, Aram
    Sahai, Amarpal
    Azab, Mohammad
    Tolcher, Anthony W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 463 - 471
  • [48] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [49] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Raoul Tibes
    Gil Fine
    Gavin Choy
    Sanjeev Redkar
    Pietro Taverna
    Aram Oganesian
    Amarpal Sahai
    Mohammad Azab
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 463 - 471
  • [50] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
    Wei, Xiao-Li
    Liu, Fu-Rong
    Liu, Ji-Hong
    Zhao, Hong-Yun
    Zhang, Yang
    Wang, Zhi-Qiang
    Qiu, Miao-Zhen
    Xu, Fei
    Yu, Qiu-Qiong
    Du, Yi-Wu
    Shi, Yan-Xia
    Wang, De-Sheng
    Wang, Feng-Hua
    Xu, Rui-Hua
    NATURE COMMUNICATIONS, 2022, 13 (01)
12345